Recent clinical research suggested that Nivolumab and Anlotinib as new combination therapy have shown promising treatment results in advanced stomach and esophageal cancer. The research was ...
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive In the ...